Image Sourced ShutterStock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Healthia has entered binding agreements to acquire four hand therapy clinics in Sydney, NSW
  • The company purchased the hand therapy clinics for $3.5 million
  • The clinics are expected to bring in a revenue of $2.7 million

Healthia has entered binding agreements to acquire four hand therapy clinics in Sydney, NSW.

The company acquired the hand therapy clinics for $3.5 million.

The clinics will be funded by the company utilising the undrawn debt available under the facility agreement with ANZ and BOQ.

Healthia is an integrated group of health based companies whose mission is to enrich lives of people through world-class health services.

The group includes My FootDr, Allsports Physiotherapy, Extend Rehabilitation, iOrthotics and D.B.S. Medical Supplies.

The company is currently Australasia’s (Australia, New Zealand and neighbouring islands) leading allied health group.

CEO of the company’s physiotherapy branch Tony Ganter is happy with the acquisition.

“The four speciality hand therapy clinics, which provide physiotherapy and occupational therapy for the hand and upper limb, complement our existing nine Extend Hand Therapy clinics in Queensland,” he said.

Hand Therapy is evaluating and treating injuries and conditions in the shoulder, arm, elbow, forearm, wrist and hand.

The clinics are expected to bring in a revenue of $2.7 million.

“We are pleased that we are able to expand these speciality services across the group,” Tony said.

Healthia’s share price has increased 2.37 per cent today and is currently selling shares at $1.08 per share.

HLA by the numbers
More From The Market Online
Image of the human circulatory system

4DMedical secures $1.9M grant to ramp-up trials for ‘safer, cheaper’ lung imaging

The Federal government has awarded 4DMedical Ltd a grant worth $1.9M to fund its clinical trials…
Closeup of IV fluid

Tryptamine psilocin treatment ruled safe in IV infusion during early trial

Tryptamine Therapeutics Ltd has been told by a Safety Committee that its IV-infused psilocin therapy is…
Australian currency

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

InhaleRX is set to go ahead with clinical trials after Victorian VC firm Clendon handed IRX…
Image of hands holding money

Telix Pharmaceuticals’ quarterly revenue exceeds AU$200M

Telix Pharmaceuticals (ASX:TLX) reveals its quarterly revenues while also reaffirming its full-year 2024 revenue guidance.